Qualitätsbericht 2022 47 | 70 Thema Fachgebiet Ansprechperson Lindenhofgruppe Kooperationspartner / Sponsor Erfassung der mittels ESD-Technik resezierten Tumoren im Gastrointestinaltrakt in den letzten 10 Jahren. Wie ist die Erfolgsrate? Welche Tumoren lassen sich mittels ESD behandeln? Komplikationsrate? Gastroenterologie PD Dr. med. Peter Netzer Diagnostik der Laktoseintoleranz per Biopsie-basiertem Laktase-Schnelltest im klinischen Alltag Gastroenterologie PD Dr. med. Peter Netzer Predictive value of ultraso-nographic parameters for therapy response in Crohn’s disease and ulcerative colitis patients (TRUST BEYOND - 829) Gastroenterologie Prof. Dr. med. Frank Seibold AbbVie A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis (20170104) Gastroenterologie Prof. Dr. med. Frank Seibold Amgen A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis (APD334-301) Gastroenterologie Prof. Dr. med. Frank Seibold ARENA A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Crohn’s Disease (BMSTYK2CDTYK2CD / IM011-023 (Lattice)) Gastroenterologie Prof. Dr. med. Frank Seibold Bristol Meyers Squibb Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod ad Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease (Ozanimod_RPC013201_Induction_MC + Ozanimod_RPC01-3203_Maintenance_MC) Gastroenterologie Prof. Dr. med. Frank Seibold Celgene Ozanimod Induction, Maintenance, and Open-Label Extension Studies for Crohn’s Disease Patients (Yellowstone) Gastroenterologie Prof. Dr. med. Frank Seibold Celgene A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (I6T-MC-AMBG_Lucent 2) Gastroenterologie Prof. Dr. med. Frank Seibold Eli Lilly A Phase 3, Multicenter, Long-Term, Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (I6T-MC-AMAP_Lucent 3) Gastroenterologie Prof. Dr. med. Frank Seibold Eli Lilly A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evalu-ate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn’s Disease (I6T-MC-AMAM_Vivid 1) Gastroenterologie Prof. Dr. med. Frank Seibold Eli Lilly
RkJQdWJsaXNoZXIy MzQxOTE=